Skip to Content

Eptifibatide Injection

Last Updated: May 26, 2020
Status: Current

Products Affected - Description
    • Integrilin injection, Merck, 2 mg/mL, 100 mL vial, 1 count, NDC 00085-1177-02
    • Eptifibatide injection, Akorn, 0.75 mg/mL, 100 mL vial, 1 count, NDC 17478-0903-90
    • Eptifibatide injection, Akorn, 2 mg/mL, 10 mL vial, 1 count, NDC 17478-0902-10
    • Eptifibatide injection, Amneal, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70121-1003-01
    • Eptifibatide injection, Amneal, 2 mg/mL, 10 mL vial, 1 count, NDC 70121-1002-01
    • Eptifibatide injection, AuroMedics, 0.75 mg/mL, 100 mL vial, 1 count, NDC 55150-0218-99
    • Eptifibatide injection, AuroMedics, 2 mg/mL, 100 mL vial, 1 count, NDC 55150-0220-99
    • Eptifibatide injection, Sagent, 0.75 mg/mL, 100 mL vial, 1 count, NDC 25021-0408-51
    • Eptifibatide injection, Sagent, 2 mg/mL, 10 mL vial, 1 count, NDC 25021-0409-10
Reason for the Shortage
    • Accord has temporarily discontinued eptifibatide injection.
    • Akorn did not provide a reason for the shortage.
    • Amneal did not provide a reason for the shortage.
    • Auromedics did not provide a reason for the shortage.
    • Baxter has eptifibatide injection available.
    • Merck did not provide a reason for the shortage.
    • Mylan has eptifibatide injection available.
    • Sagent states the shortage is due to manufacturing delay.
    • Slate Run has eptifibatide injection available.
Available Products
    • Integrilin injection, Merck, 0.75 mg/mL, 100 mL vial, 1 count, NDC 00085-1136-01
    • Integrilin injection, Merck, 2 mg/mL, 10 mL vial, 1 count, NDC 00085-1177-01
    • Eptifibatide injection, AuroMedics, 2 mg/mL, 10 mL vial, 1 count, NDC 55150-0219-10
    • Eptifibatide injection, Baxter, 0.75 mg/mL, 100 mL vial, 1 count, NDC 00338-9558-10
    • Eptifibatide injection, Mylan Institutional, 0.75 mg/mL, 100 mL vial, 1 count, NDC 67457-0631-10
    • Eptifibatide injection, Mylan Institutional, 2 mg/mL, 10 mL vial, 1 count, NDC 67457-0629-10
    • Eptifibatide injection, Mylan Institutional, 2 mg/mL, 100 mL vial, 1 count, NDC 67457-0630-10
    • Eptifibatide injection, Slate Run Pharmaceuticals, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70436-0027-80
    • Eptifibatide injection, Slate Run Pharmaceuticals, 2 mg/mL, 10 mL vial, 1 count, NDC 70436-0026-80

Estimated Resupply Dates

    • Akorn has eptifibatide 0.75 mg/mL in 100 mL vials and 2 mg/mL in 10 mL vials on back order and the company estimates a release date in mid-June 2020.
    • Amneal has eptifibatide 0.75 mg/mL in 100 mL vials and 2 mg/mL in 10 mL vials on back order and the company cannot estimate a release date.
    • Auromedics has eptifibatide 0.75 mg/mL and 2 mg/mL in 100 mL vials on intermittent back order and the company is releasing product as it becomes available.
    • Merck has Integrilin 2 mg/mL in 100 mL vials on back order and the company cannot estimate a release date.
    • Sagent has eptifibatide 0.75 mg/mL in 100 mL vials and 2 mg/mL in 10 mL vials on back order and the company estimates release dates in June 2020.

Updated

Updated May 26, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created May 21, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide